{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:04:45Z","timestamp":1790899485833,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The current coronavirus disease (COVID-19) pandemic is showing no signs of abatement and result in significant morbidity and mortality in the infected patients. Many therapeutic agents ranging widely between antivirals and anti-inflammatory drugs have been used to mitigate the disease burden. In the deluge of the drugs being used for COVID-19 infection, glucocorticoids (GCs) stand out by reducing mortality amongst in-hospital severe-to-critically ill patients. Health-care practitioners have seen this as a glimmer of hope and started using these drugs more frequently than ever in clinical practice. The fear of mortality in the short term has overridden the concern of adverse long-term consequences with steroid use. The ease of availability, low cost, and apparent clinical improvement in the short term have led to the unscrupulous use of the steroids even in mild COVID-19 patients including self-medication with steroids. The use of GCs has led to the increasing incidence of hyperglycemia and consequent acute complications of diabetic ketoacidosis and mucormycosis in COVID-19 patients. There is an urgent need to dissipate information about optimum management of hyperglycemia during steroid use. In view of this, the Endocrine Society of India has formulated this position statement about the diagnosis and management of hyperglycemia due to the use of GCs in patients with COVID-19 infection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijem.ijem_227_21","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T02:37:53Z","timestamp":1626835073000},"page":"4-11","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Diagnosis and Management Considerations in Steroid-Related Hyperglycemia in COVID-19"],"prefix":"10.4103","volume":"25","author":[{"given":"Sambit","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashu","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. V. S.","family":"Harikumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deep","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Sahay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujoy","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushik","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. K.","family":"Jabbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Damodaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Sri","family":"Nagesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehla","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. V.","family":"Madhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganapathi","family":"Bantwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20240828","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"R2-2-20240828","first-page":"1","article-title":"Diabetes prevalence and mortality in COVID-19 patients: A systematic review, meta-analysis, and meta-regression","volume":"31","author":"Saha","year":"2021","journal-title":"J Diabetes Metab Disord"},{"key":"R3-2-20240828","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1007\/s00125-020-05180-x","article-title":"CORONADO investigators.Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: The CORONADO study","volume":"63","author":"Cariou","year":"2020","journal-title":"Diabetologia"},{"key":"R4-2-20240828","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S2213-8587(20)30152-2","article-title":"Practical recommendations for the management of diabetes in patients with COVID-19","volume":"8","author":"Bornstein","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R5-2-20240828","doi-asserted-by":"crossref","first-page":"107927","DOI":"10.1016\/j.jdiacomp.2021.107927","article-title":"Pharmacological management of COVID-19 in type 2 diabetes?","volume":"17","author":"Ceriello","year":"2021","journal-title":"J Diabetes Complications"},{"key":"R6-2-20240828","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.dsx.2021.01.015","article-title":"A guidance on diagnosis and management of hyperglycemia at COVID care facilities in India","volume":"15","author":"Gupta","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"R7-2-20240828","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A Meta-analysis","volume":"324","author":"Sterne","year":"2020","journal-title":"JAMA"},{"key":"R8-2-20240828","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMc2018688","article-title":"New-Onset Diabetes in Covid-19","volume":"383","author":"Rubino","year":"2020","journal-title":"N Engl J Med"},{"key":"R9-2-20240828","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/dme.13675","article-title":"Management of hyperglycemia and steroid (glucocorticoid) therapy: A guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group","volume":"35","author":"Roberts","year":"2018","journal-title":"Diabet Med"},{"key":"R10-2-20240828","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2337\/dc09-9029","article-title":"American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control","volume":"32","author":"Moghissi","year":"2009","journal-title":"Diabetes Care"},{"key":"R11-2-20240828","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4158\/EP08331.RAR","article-title":"Glucocorticoid-induced hyperglycemia","volume":"15","author":"Clore","year":"2009","journal-title":"Endocr Pract"},{"key":"R12-2-20240828","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.diabres.2012.12.023","article-title":"The high incidence of steroid-induced hyperglycaemia in hospital","volume":"99","author":"Fong","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"R13-2-20240828","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s00125-005-1886-0","article-title":"Glucocorticoid-induced insulin resistance in skeletal muscles: Defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor","volume":"48","author":"Ruzzin","year":"2005","journal-title":"Diabetologia"},{"key":"R16-2-20240828","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S2666-7568(20)30033-7","article-title":"Metformin and risk of mortality in patients hospitalised with COVID-19: A retrospective cohort analysis","volume":"2","author":"Bramante","year":"2021","journal-title":"Lancet Healthy Longev"},{"key":"R17-2-20240828","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.2337\/diacare.25.12.2359","article-title":"Efficacy of glimepiride for the treatment of diabetes occurring during glucocorticoid therapy","volume":"25","author":"Kasayama","year":"2002","journal-title":"Diabetes Care"},{"key":"R18-2-20240828","doi-asserted-by":"crossref","first-page":"e13529","DOI":"10.1111\/ijcp.13529","article-title":"Oral treatment of glucocorticoid-induced diabetes mellitus: A systematic review","volume":"74","author":"Klarskov","year":"2020","journal-title":"Int J Clin Pract"},{"key":"R19-2-20240828","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/1753-0407.12090","article-title":"Glucocorticoid-induced hyperglycemia","volume":"6","author":"Perez","year":"2014","journal-title":"J Diabetes"},{"key":"R20-2-20240828","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0168-8227(02)00127-4","article-title":"Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes","volume":"58","author":"Willi","year":"2002","journal-title":"Diabetes Res Clin Pract"},{"key":"R21-2-20240828","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12902-020-00561-0","article-title":"Study rationale and design of the EANITIATE study (EmpAgliflozin compared to NPH Insulin for sTeroId diAbeTEs)-a randomized, controlled, multicenter trial of safety and efficacy of treatment with empagliflozin compared with NPH-insulin in patients with newly onset diabetes following initiation of glucocorticoid treatment","volume":"20","author":"Klarskov","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"R22-2-20240828","doi-asserted-by":"crossref","first-page":"e14378","DOI":"10.1111\/dme.14378","article-title":"Dexamethasone therapy in COVID-19 patients: Implications and guidance for the management of blood glucose in people with and without diabetes","volume":"38","author":"Rayman","year":"2021","journal-title":"Diabet Med"},{"key":"R23-2-20240828","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ecl.2016.06.013","article-title":"Inpatient diabetes management in the twenty-first century","volume":"45","author":"Khazai","year":"2016","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R24-2-20240828","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4158\/EP15818.OR","article-title":"Hospital insulin protocol aims for glucose control in glucocorticoid-induced hyperglycemia","volume":"22","author":"Grommesh","year":"2016","journal-title":"Endocr Pract"},{"key":"R25-2-20240828","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4158\/EP11260.OR","article-title":"Adapting to the new consensus guidelines for managing hyperglycemia during critical illness: The updated Yale insulin infusion protocol","volume":"18","author":"Shetty","year":"2012","journal-title":"Endocr Pract"},{"key":"R26-2-20240828","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2337\/diaspect.27.3.218","article-title":"Continuous insulin infusion: When, where, and how?","volume":"27","author":"Kelly","year":"2014","journal-title":"Diabetes Spectr"},{"key":"R27-2-20240828","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3949\/ccjm.78a.10180","article-title":"Glucocorticoid-induced diabetes and adrenal suppression: How to detect and manage them","volume":"78","author":"Lansang","year":"2011","journal-title":"Cleve Clin J Med"},{"key":"R28-2-20240828","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.4103\/2230-8210.123548","article-title":"Management issues with exogenous steroid therapy","volume":"17","author":"Patt","year":"2013","journal-title":"Indian J Endocr Metab"},{"key":"R29-2-20240828","first-page":"1","article-title":"Improved glycemic control amongst people with long-standing diabetes during COVID-19 lockdown: A prospective, observational, nested cohort study","volume":"21","author":"Rastogi","year":"2020","journal-title":"Int J Diabetes Dev Ctries"},{"key":"R30-2-20240828","doi-asserted-by":"crossref","first-page":"e0251143","DOI":"10.1371\/journal.pone.0251143","article-title":"Virtual triage and outcomes of diabetic foot complications during Covid-19 pandemic: A retro-prospective, observational cohort study","volume":"16","author":"Rastogi","year":"2021","journal-title":"PLoS One"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_227_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:28:33Z","timestamp":1786735713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_227_21"}},"subtitle":["A Position Statement from the Endocrine Society of India"],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijem.ijem_227_21","relation":{},"ISSN":["2230-8210"],"issn-type":[{"value":"2230-8210","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}